Day: November 13

Industry innovation in diagnostic technologies and targeted treatment strategies drives progress in personalized medicine. But the path to market is fraught with obstacles. Pioneering investors and executives reflect on how to deal with challenges and uncertainty in an increasingly variable development and market environment.

This session explores the cutting edge of personalized medicine beyond traditional gene testing, highlighting the clinical integration of next-generation diagnostic technologies. Experts will discuss the promise and practical application of proteomics, metagenomics, circulating tumor DNA (ctDNA), and digital diagnostic tools in delivering more precise, timely, and individualized care.

SPEAKER | Daryl Pritchard, Ph.D., President, Personalized Medicine Coalition